Vetter Opens Technologically Advanced Service Facility In The U.S., Strengthening Commitment To North American Market
One of the world's leading providers of aseptically pre-filled injection systems, Vetter will open Vetter Development Service (VDS), a technologically advanced customer service facility located in Chicago, allowing the company to provide greater commitment and support toward the product needs of its North American customers. Using state-of-the-art technology, Vetter will be capable of aseptically filling very small quantities of products in the new facility, providing faster and more streamlined product delivery and customer service. Headquartered in Ravensburg, Germany, Vetter sees the new facility as a major investment in Vetter Pharma International GmbH.
Working hand-in-hand with customers from clinical development through to market launch has allowed Vetter to develop an ideal mode of delivery for highly sensitive, active ingredients. With its new location in the heart of the United States, Vetter can now process and test small quantities of materials by bringing the development process closer to many key customers, enabling greater cooperation at the earliest stages of development and minimizing the need to transport products.
For Vetter's many North American customers, a shorter time to market will soon be facilitated, by its Chicago location according to Peter Soelkner, Managing Director at Vetter. "The opening of this new cutting-edge VDS facility shows Vetter's firm, strategic commitment to the North American market by bringing the state of the art technology to the heart of the U.S.," said Peter Soelkner. "The support VDS delivers throughout the entire product development cycle can now start earlier, and the proximity to our customers will contribute to streamlining the process and delivering the final product faster."
Located in Chicago, the new approx 25.000 square feet VDS facility will open end of 2009.
About Vetter
Vetter is an independent international specialist in the aseptic filling of syringes, cartridges and vials. Based in Ravensburg, Germany, Vetter also produces its own injection systems, such as the Vetter Lyo-Ject dual-chamber syringe. With about 1,900 employees worldwide, Vetter holds nearly 140 patents and has longstanding experience in handling client products and processes approved by the FDA, the EMEA and other authorities. In 2007, the company also received the go-ahead as a foreign manufacturer for the Japanese pharmaceutical market from Japan's Ministry for Health, Labor and Welfare. Additionally, Vetter has received two awards for its new facility Ravensburg Vetter South (RVS): The Facility of the Year Award 2007 (Process Innovation category) and the European Outsourcing Award 2007 (Most Improved Process/Plant/Facility category). For more information, visit www.vetter-pharma.com
Vetter Development Service provides support for its pharmaceutical and biotech clients in the early stages of development, from clinical phases and regulatory approval to worldwide product launch. Vetter Commercial Manufacturing handles the entire production process, from compounding and aseptic filling to the final packaging of a product. Vetter Solutions' patented application systems enable clients to compete more effectively throughout the world.
SOURCE: Vetter